GENPREX (NASDAQ:GNPX – Get Free Report)‘s stock had its “sell (e+)” rating reaffirmed by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.
GENPREX Stock Up 20.8%
GNPX opened at $0.24 on Wednesday. GENPREX has a 12 month low of $0.14 and a 12 month high of $3.97. The firm’s fifty day simple moving average is $0.21 and its 200 day simple moving average is $0.25.
GENPREX (NASDAQ:GNPX – Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.54. On average, research analysts predict that GENPREX will post -5.7 earnings per share for the current year.
About GENPREX
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
Further Reading
- Five stocks we like better than GENPREX
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- Find and Profitably Trade Stocks at 52-Week Lows
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Receive News & Ratings for GENPREX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENPREX and related companies with MarketBeat.com's FREE daily email newsletter.
